Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Kartik Sehgal(Beth Israel Deaconess Medical Center), Madhav V. Dhodapkar(Emory University), Yan Ren, Yanhong Deng(Sun Yat-sen University), Anjan Thakurta(University of Oxford), Maria Wang, Suzana S. Couto, Mehmet H. Kocoglu(University of Maryland, Baltimore), Juan C. Vasquez(Yale University), Dennis Cooper(Yale Cancer Center), Srinivas V. Koduru, Kavita M. Dhodapkar(Emory University), Lin Zhang(Mudanjiang Medical University), Rakesh Verma(Harvard University), Stuart Seropian(Yale Cancer Center), Mike A. Breider, Donna E. Hansel(The University of Texas MD Anderson Cancer Center), Xiaopan Yao(Dana-Farber Cancer Institute), Rituparna Das
Cited by 133
Related Papers
Is a p53-Regulated Inhibitor of G2/M Progression
|Molecular Cell|1997|1.2k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907
Analysis of human transcriptomes
|Nature Genetics|1999|789